You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies

Article info

Article menu

Download PDFPDF

XML
Epidemiology/Health Services Research
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies

Authors

  • Bhavani Shankara Bagepally Non-Communicable Diseases, ICMR-National Institute of Epidemiology, Chennai, IndiaMahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Usa Chaikledkaew Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, ThailandSocial and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Yogesh Krishnarao Gurav Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, ThailandEpidemiology Group, ICMR-National Institute of Virology, Pune, India PubMed articlesGoogle scholar articles
  • Thunyarat Anothaisintawee Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, ThailandDepartment of Family Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Sitaporn Youngkong Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, ThailandSocial and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Nathorn Chaiyakunapruk College of Pharmacy, University of Utah, Salt Lake City, Utah, USA PubMed articlesGoogle scholar articles
  • Mark McEvoy Centre for Clinical Epidemiology and Biostatistics, Hunter Medical Research Institute, School of Medicine and Public Health, University of Newcastle, New Lambton, New South Wales, Australia PubMed articlesGoogle scholar articles
  • John Attia Centre for Clinical Epidemiology and Biostatistics, Hunter Medical Research Institute, School of Medicine and Public Health, University of Newcastle, New Lambton, New South Wales, AustraliaDivision of Medicine, John Hunter Hospital, New Lambton, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ammarin Thakkinstian Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, ThailandDepartment of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Usa Chaikledkaew; usa.chi{at}mahidol.ac.th
View Full Text

Citation

Bagepally BS, Chaikledkaew U, Gurav YK, et al
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
BMJ Open Diabetes Research and Care 2020;8:e001020. doi: 10.1136/bmjdrc-2019-001020

Publication history

  • Received November 4, 2019
  • Revised February 26, 2020
  • Accepted June 8, 2020
  • First published July 19, 2020.
Online issue publication 
July 19, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.